Nanobac Pharmaceuticals Films Stunning Details of
Seite 1 von 2
neuester Beitrag: 29.10.06 18:14
|eröffnet am:||22.08.06 23:29 von:||horstpaul||Anzahl Beiträge:||38|
|neuester Beitrag:||29.10.06 18:14 von:||Bobby333||Leser gesamt:||4602|
|bewertet mit 2 Sternen
horstpaul : Nanobac Pharmaceuticals Films Stunning Details of
Nanobac Pharmaceuticals Films Stunning Details of Nanoparticles Using New Technology
TUESDAY, AUGUST 22, 2006 12:26 PM
TAMPA, Fla., Aug 22, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced that its scientists have obtained new details about interactions of drugs with calcifying nanoparticles (CNPs), known also as nanobacteria, using award-winning light microscope technology.
The images show nanoparticles being affected by a therapeutic drug ingredient, and offer proof of concept that new microscope technology can detect real-time processes surrounding calcifying nanoparticles, which contain harmful calcifying constituents found in diseases such as kidney stones and atherosclerosis.
"This marks a watershed in the Company's ability to witness interactions between drug ingredients and calcifying nanoparticles," commented Nanobac Co-Chairman Dr. Benedict Maniscalco. "These images also demonstrate clear differences between CNPs and inorganic apatite, offering further proof that CNPs are distinct from inorganic apatite particles."
The video and still images were obtained by Nanobac scientists Dr. Neva Ciftcioglu and Grace Mathew at Nanobac laboratories in the NASA Johnson Space Center in Houston. The images will be released once the processes they recorded have been validated.
The success is an early result of a collaboration agreement between Nanobac and the Fetzer Memorial Trust to photograph the replication cycle of disease-related calcifying particles (also known as nanobacteria or Calcifying Nanoparticles), using light microscopes to break the 200 nanometer ("nm") resolution barrier. The breakthrough may allow Nanobac scientists to determine if calcification, which occurs in most diseases on the leading causes of death list, has a biological mechanism, which would make it susceptible to therapy.
Until now, scientists had to 'fix' or inactivate such nanoparticles to see below the 200 nmhreshold using electron microscopy, which precluded observing real-time processes.
The "CytoViva"(TM) microscope system, developed at Auburn University and marketed by Aetos Technologies, can resolve details at or below 100 nm and detect particles as small as 50 nm, representing a significant improvement over conventional light microscopes. The CytoViva(TM) system was selected in June by R&D Magazine as one of the top 100 most technologically significant products introduced to the marketplace in 2006. The award is often referred to as the 'Oscar of Inventions.'
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.
Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .
Nukem : Ticker!
NANOBAC PHARMACEUTICALS aufmerksamaufmerksamaufmerksamaufmerksam
OTCPicks.com: Daily Market Movers Digest Stock Alerts, Monday, September 25th, EDNE, XKEM, GLIF, NNBP, ABTG
Sep 25, 2006 (M2 PRESSWIRE via COMTEX News Network) --
Today our stock watch alerts today include stock alerts for Eden Energy Corporation (OTCBB: EDNE), Xechem International, Inc. (OTCBB: XKEM), Grant Life Sciences, Inc. (OTCBB: GLIF), Nanobac Pharmaceuticals, Inc. (OTCBB: NNBP), and Ambient Corporation (OTCBB: ABTG)
Visit http://www.otcpicks.com to register for our FREE Daily Market Mover\'s Digest Newsletter and Stock Alerts
horstpaul : Da sind schon die ersten wirklich guten news :)
TAMPA, Fla., Oct 04, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (NNBP) ("Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases. CNPs have been found in preliminary studies to be markers of arterial calcification, which in turn is a reliable marker of heart disease risk. AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S.
"Nanobac has partnered with AHA for this important test so that our company can focus on its core R&D while continuing to make available and expanding the availability of these tests for research purposes," explained Nanobac Co-Chairman Dr. Benedict Maniscalco. "For the first time ever we now have a qualified laboratory in the U.S. where physicians can send blood samples for testing, along with authorized stations where patients can go to have blood drawn and know that the samples will be properly handled," Dr. Maniscalco added.
The tests can detect CNP antigens and antibodies. Analysis is done by Nanobac's own laboratories in Kuopio Finland; the only lab in the world capable of such analysis. Nanobac has performed thousands of such tests worldwide since the year 2000.
(a) (Note to editors: the term "Calcifying Nanoparticle (CNP)" has been adopted in recently published literature to help distinguish these particles from bacteria.)
About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria." The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.
Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Calibra21 : Welches Kursziel ?
...Die Analysten von Wall Street Research hätten für die Aktie ein Kursziel von 0,91 USD in Aussicht gestellt. Die "Hot Stocks Investor"-Experten würden das auf kurze Sicht aber als etwas zu hoch ansehen. Ein Run bis in den Bereich von 50 bis 60 Cents könnte aber durchaus noch drin sein...
Calibra21 : Genau wie GLIF wird anscheinend
...have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases...
hhsjgmr : das glaube ich nicht calibra21
in den USA gestern bei 0,21$ geschlossen, plus "nur" 2,0%
wenn ich aber sehe, das sie seit Juli August ca.300%
dann würde ich den Kurs hier nicht über Pari
sonst kommen die Amis noch auf den Gedanken erstmal
es ist Freitag ich sag immer "Verkaufstag" und damit bin
ich bisher immer gut gefahren
Nukem : Gestrige News
Tuesday October 24, 12:52 pm ET
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News) has enlisted The Aker Partners Inc. to implement a comprehensive national media relations program.
Nanobac is a growing pharmaceutical company in the field of medical nanotechnology. The company\'s focus is on developing methods to treat calcifying nanoparticles (CNPs), and by doing so, find more effective approaches to treating and preventing the cardiovascular, kidney and prostate diseases associated with them.
"Nanobac is deep into landmark medical research that we believe will redefine the way we view disease and change the way physicians approach the treatment of illnesses," said Nanobac Co-Chairman Dr. Benedict Maniscalco. "We believe utilizing the experienced professionals at The Aker Partners will not only increase the visibility of our work in the field of medical nanotechnology, but also enhance the viability of our company."
Nanotechnology is the realm of discovering and exploiting the special characteristics of materials at the atomic scale. A nanoparticle is generally considered to be anything less than 100 nanometers, or 100 billionths of a meter. If a one-meter ruler could be stretched from New York City to Los Angeles, a nanometer on that ruler would still be only the size of an aspirin.
The specialized type of medical nanotechnology being pursued by Nanobac aims to combat disease on that "nano" scale by detecting calcifying nanoparticles that straddle the 100 nanometer size line, ranging in diameter from 75 nm to more than 500 nm. Researchers believe these CNPs are the basic cause of a multitude of illnesses.
Based in Washington, D.C., The Aker Partners is a specialist in the health care industry and has broad experience in the rapidly growing field of medical nanotechnology. The agency has engineered successful communications campaigns for companies utilizing nanotechnology and is at the forefront of the effort to educate the public about the positive medical implications of the technology.
"Over the last 24 years our firm has helped more than 500 clients tell their compelling stories and communicate their accomplishments," said Aker Partners Manager Partner Colburn Aker. "The breakthroughs occurring at Nanobac are some of the most unique stories we have ever had the opportunity to help communicate."
Nanobac Pharmaceuticals Inc., based in Tampa, FL, is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). The company\'s pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in prostate, gall bladder and vascular disease. Nanobac\'s drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac\'s BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. For details visit http://www.nanobac.com.
The Aker Partners Inc.
Since its founding in 1983, Washington-based The Aker Partners has represented more than 500 clients, providing public affairs, health care and marketing communications, plus its trademarked NetPR® Internet communications service. It is the nation\'s only Partner-Directed Communications and Marketing® firm and also serves as the Washington office of the Public Relations Global Network Inc.,® which offers clients more than 50 offices worldwide. For more information, visit www.akerpartners.com.
Nanobac Pharmaceuticals Inc., Tampa
Douglas Mulhall, 813-264-2241
Jens Dalsgaard, 415-884-0348
Source: Nanobac Pharmaceuticals Inc.
Nukem : Kunden 260%RevenueSteigerung mit guter PR
Wenn man das liest, was die Kunden über die PR-Agentur sagen, dann liest sich dass ganz gut. Verkaufssteigerungen über 260% usw. Sogar Ford hatte seinen Hybrid rausputzen lassen. Interessant.
Vielleicht funktionierts ja auch bei NNBP.
There were only 16 shopping days until Christmas and Geezer.com, the first Web site selling the crafts of senior artisans badly needed publicity. In order to attract potential holiday buyers, we launched a netPR® campaign, increasing sales by more than 260%.
Für Ford wurde der Hybrid rausgekehrt.
biomuell : Nanobac: zweifelhaft und umstritten
Nanobac Pharmaceuticals Inc. Signs Agreement with American Health Associates Clinical Laboratories to Provide Calcifying Nanoparticle Tests in the United States
...wurde vor ein paar tagen veröffentlicht. DAS PROBLEM: mach mal eine google-suche - American Health Associates Clinical Laboratories..wirst Du nicht finden. Ein Schelm, wer böses denkt...
Nanobac ist spätest in 6 Monate pleite, die haben offenbar dringenst Publicity notwendig um an neue Investoren zu kommen und sich selbst am Leben zu erhalten....
...das ganze ungeachtet der Wissenschaftlichkeit, die hinter den "Nanobacterien" steht......
biomuell : nichtsdestotrotz, ich verfolge NNBP
horstpaul : @biomuell
Hab auch nochmal die Yellowbooks gechecked und in Miramar [FL] nur 1 "Clinical Laboratory" gefunden und zwar "Quest Diagnostics Inc" (Kürzel: DGX, schönes GAP nach unten btw. ;)).
Muss dir zustimmen, dass das alles sehr seltsam ist. Falls jemand versierter in Englisch ist, als ich, wäre es sehr interessant zu hören, was die Herren von Nanobac dazu zu sagen haben.
Investor Feedback: http://www.nanobac.com/content/feedback.cfm
Oder einfach per Telefon: For a telephone consultation, please call
Redwood Consultants, LLC (415) 884-0348
oder direkt bei Nanobac:
Phone: (813) 264-2241
Calibra21 : @ biomuell und horstpaul
KEIN PROBLEM !
Schaut mal hier: https://www.americanhealthlab.com/splashPage.hg
7660 66th Street North
Pinellas Park, FL 33781
Immer zuerst das Gute im Menschen sehen.
Bobby333 : @ den Müllman...